A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study
Shun Lü(Shanghai Jiao Tong University), Weiguo Su(Tamedia (Switzerland)), Buhai Wang(Northern Jiangsu People's Hospital), Wangjun Liao(Sun Yat-sen University), Yijiang Huang(Hainan General Hospital), Zhendong Zheng(General Hospital of Shenyang Military Region), Shukui Qin(81th Hospital of PLA), Hongming Pan(Sir Run Run Shaw Hospital), Zhijun Jie(Fudan University), Sha Guan, Jianying Zhou(First Affiliated Hospital Zhejiang University), Zhe Liu(Capital Medical University), Ying Cheng(Jilin Province Tumor Hospital), Yanping Hu(Chinese People's Liberation Army), Youling Gong(Dalian Medical University), Mingfang Liu(Ningxia Medical University), Jian Fang(Peking University), Mengye Peng, Wěi Li(Shougang (China)), Shan Li(Army Medical University), Feng Qiu(Jiangsu University), Feng Ye(Shanghai Sunshine Rehabilitation Center), Yuan Chen(Tongji Hospital), Yong Song(Nanjing General Hospital of Nanjing Military Command), Chunhong Hu(Central South University), Li Liang(Jiangsu University), Jin‐Ji Yang(Guangdong General Hospital), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Zhendong Chen(University of Cologne), Yiping Zhang(Henan Normal University), Jianhua Shi(Linyi People's Hospital), Zhixiong Yang(Guangdong Medical College), Rui Ma(Liaoning Cancer Hospital & Institute), Yunchao Huang(North China University of Water Resources and Electric Power), Min Tao(Shanghai East Hospital), Sanyuan Sun(Xuzhou Central Hospital), Yuping Sun(Henan Academy of Agricultural Sciences), Chong Bai(Second Military Medical University), Dongning Huang(Fourth Affiliated Hospital of Guangxi Medical University), Yu Yao(First Affiliated Hospital of Xi'an Jiaotong University), Shenglin Ma(North University of China), Lejie Cao(University of Science and Technology of China), Xiaoqing Liu(Chinese PLA General Hospital), Gongyan Chen(Harbin Medical University), Jianhua Chang(Shanghai Medical College of Fudan University), Weidong Mao(Xuzhou Medical College), Zhihua Liu(California Institute of Technology), Jun‐Guo Lu(Ministry of Industry and Information Technology)
Cited by 21
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k